Denmark· DK-28106594021
Kaftrio
A ivacaftor, tezacaftor and elexacaftor product containing elexacaftor, ivacaftor, tezacaftor, registered in Denmark by Vertex Pharmaceuticals (Ireland) Limited. The same ATC class is registered in 14 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Ivacaftor, tezacaftor and elexacaftor is registered in 14 of 19 countries.
Countries holding a registration under ATC R07AX32 (ivacaftor, tezacaftor and elexacaftor), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 9 of them publish a price we can compare per daily dose
Ivacaftor, tezacaftor and elexacaftor · ATC R07AX32
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Elexacaftor, Ivacaftor, Tezacaftor
- Manufacturer
- Vertex Pharmaceuticals (Ireland) Limited
- Country
- Denmark (DK)
- ATC code
- R07AX32
- ATC class
- Ivacaftor, tezacaftor and elexacaftor
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106594021
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
14 interactions on record for ivacaftor, tezacaftor and elexacaftor.
Graded by severity as the source publishes them — 14 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ivacaftor, tezacaftor and elexacaftor · interactions on record
14 records
- 14 moderate
Most severe, free to view
- RifaximinA07AA11moderate
- EmpagliflozinA10BK03moderate
- RepaglinideA10BX02moderate
- EmpagliflozinA10BX12moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under R07AX32
Ivacaftor, tezacaftor and elexacaftor, as other registers publish it.
- PolandKaftrioVertex Pharmaceuticals (Ireland) Ltd.
- FinlandKaftrioVertex Pharmaceuticals (Europe) Limited
- PolandKaftrioVertex Pharmaceuticals (Ireland) Ltd.
- FinlandKaftrioVertex Pharmaceuticals (Europe) Limited
- FinlandKaftrioVertex Pharmaceuticals (Europe) Limited
- FinlandKaftrioVertex Pharmaceuticals (Europe) Limited
- NorwayKaftrioVertex Pharmaceuticals (Ireland) Limited
- PolandKaftrioVertex Pharmaceuticals (Ireland) Ltd.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cfb02b24-4b30-45c3-ad9d-1ca4a4e3da98 GET /v1/drugs/cfb02b24-4b30-45c3-ad9d-1ca4a4e3da98?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "filmovertrukne tabletter",
"source": "dkma",
"strength": "37,5+25+50 mg",
"auth_role": "MOD",
"dk_drugid": "28106594021",
"substance": "Elexacaftor, Ivacaftor, Tezacaftor",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "44568"
}See everything about ivacaftor, tezacaftor and elexacaftor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.